Zoetis Files 8-K for Reg FD Disclosure on Feb 6, 2024

TL;DR

**Zoetis just dropped an 8-K for Reg FD, signaling important news is out.**

AI Summary

Zoetis Inc. filed an 8-K on February 6, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. This filing, identified by accession number 0001555280-24-000030, indicates that the company is sharing important, non-public information with the public to ensure fair disclosure. For investors, this means Zoetis is likely providing updates that could impact its stock price, and they should look for the specific content of the Regulation FD disclosure to understand potential changes in the company's outlook or operations.

Why It Matters

This filing signals that Zoetis is making a significant disclosure of information that was previously non-public, which could influence investor perception and stock valuation. Investors should seek out the specific details of the Regulation FD disclosure to understand its implications.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing for Regulation FD disclosure, which aims to reduce information asymmetry and is generally a positive for transparency.

Analyst Insight

A smart investor would immediately look for the specific content of the Regulation FD disclosure and any accompanying financial statements or exhibits to understand the nature of the information being shared and its potential impact on Zoetis's future performance and stock price.

Key Players & Entities

• Zoetis Inc. (company) — the registrant filing the 8-K
• February 6, 2024 (date) — date of earliest event reported and filing date
• 001-35797 (string) — Commission File Number for Zoetis Inc.
• Delaware (string) — state of incorporation for Zoetis Inc.
• 10 Sylvan Way, Parsippany, New Jersey 07054 (string) — principal executive offices of Zoetis Inc.

FAQ

From the Filing

0001555280-24-000030.txt : 20240206 0001555280-24-000030.hdr.sgml : 20240206 20240206161905 ACCESSION NUMBER: 0001555280-24-000030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240206 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 24600511 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20240206.htm 8-K zts-20240206 0001555280 false 0001555280 2024-02-06 2024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2024 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way Parsippany New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01. Regulation FD Disclosure. On February 6, 2024, the Company declared a dividend of $0.432 per share for the second quarter of 2024. The dividend will be paid on June 4, 2024, to all holders of record of the Company’s common stock as of the close of business on April 19, 2024. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless express